Radionuclide stress tests were initially introduced into medicine as new diagnostic tests for coronary artery disease (CAD). These tests are very effective for this purpose when applied to populations with an intermediate pre-test probability of coronary artery disease. Radionuclide stress tests, however, also are used now in guiding many management decisions in patients with established CAD, based on the ability of these tests to assess the extent and severity of myocardial ischemia, the functional significance of coronary stenoses, and myocardial viability. Specific uses beyond diagnosis include decisions regarding whom to catheterize, send to coronary bypass surgery, or angioplasty; risk stratification following myocardial infarction or before noncardiac surgery; and evaluation of the results of therapy. This article reviews both the diagnostic efficacy of radionuclide stress tests and their efficacy in guiding management decisions in patients with known coronary artery disease.